866-997-4948(US-Canada Toll Free)

Peritoneal Cancer - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Feb 2014

Category :

Cancer

No. of Pages : 218 Pages

Global Markets Direct’s, ‘Peritoneal Cancer - Pipeline Review, H1 2014’, provides an overview of the Peritoneal Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Peritoneal Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Peritoneal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Peritoneal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Peritoneal Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Peritoneal Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content

Introduction
Global Markets Direct Report Coverage
Peritoneal Cancer Overview
Therapeutics Development
Pipeline Products for Peritoneal Cancer - Overview
Pipeline Products for Peritoneal Cancer - Comparative Analysis
Peritoneal Cancer - Therapeutics under Development by Companies
Peritoneal Cancer - Therapeutics under Investigation by Universities/Institutes
Peritoneal Cancer - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Peritoneal Cancer - Products under Development by Companies
Peritoneal Cancer - Products under Investigation by Universities/Institutes
Peritoneal Cancer - Companies Involved in Therapeutics Development
Boehringer Ingelheim GmbH
AstraZeneca PLC
GlaxoSmithKline plc
Bioniche Life Sciences, Inc.
Daiichi Sankyo Company, Limited
Oxford BioMedica plc
Millennium Pharmaceuticals, Inc.
Novartis AG
ImmunoGen, Inc.
Bayer AG
Incyte Corporation
Oncolytics Biotech Inc.
Pharmacyclics, Inc.
Synta Pharmaceuticals Corp.
Oasmia Pharmaceutical AB
MabVax Therapeutics, Inc.
Spectrum Pharmaceuticals, Inc.
Acceleron Pharma, Inc.
TRION Pharma GmbH
CerRx, Inc.
OncoMed Pharmaceuticals, Inc.
TetraLogic Pharmaceuticals
Innate Therapeutics Limited
CritiTech, Inc.
Immunotope, Inc.
Immunovaccine, Inc.
Pharma Mar, S.A.
VentiRx Pharmaceuticals, Inc.
Genelux Corporation
Clovis Oncology, Inc.
California Stem Cell, Inc.
EGEN, Inc.
Advanced Accelerator Applications
Peritoneal Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
pazopanib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
paclitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MEK-162 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trabectedin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sorafenib tosylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alisertib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
selumetinib sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dalantercept - Drug Profile
Product Description
Mechanism of Action
R&D Progress
elesclomol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TroVax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pelareorep - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nintedanib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
catumaxomab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VTX-2337 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
exatecan mesylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EGEN-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NSC-748933 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INCB-24360 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
birinapant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rucaparib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
metformin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cancer Stem Cell Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fenretinide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DPX-Survivac - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ganetespib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pralatrexate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
demcizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GL-ONC-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
abexinostat hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
8H9-MAb - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMT-1012 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
paclitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MV-NIS Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMGN-853 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Globo-H-GM2-sTn-TF-Tn-KLH Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OC-DC Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mycobacterial Cell Wall-DNA Complex Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MIS-416 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Theranean - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peritoneal Cancer - Recent Pipeline Updates
Peritoneal Cancer - Dormant Projects
Peritoneal Cancer - Discontinued Products
Peritoneal Cancer - Product Development Milestones
Featured News & Press Releases
Nov 01, 2012: Genelux Announces Early Results Of Phase I/II Clinical Trial Of Virotherapeutic GL-ONC1 In Advanced Peritoneal Cavity Cancers
Sep 20, 2012: Roche\'s Avastin Obtains Positive Opinion From CHMP To Treat Various Cancers
May 31, 2012: Genelux Announces Treatment Of First Patient In Phase I/II Clinical Trial Of GL-ONC1 In Advanced Peritoneal Cavity Cancers

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Table


Number of Products under Development for Peritoneal Cancer, H1 2014
Number of Products under Development for Peritoneal Cancer - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Development by Companies, H1 2014 (Contd..1)
Number of Products under Development by Companies, H1 2014 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2014
Comparative Analysis by Late Stage Development, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Development, H1 2014
Products under Development by Companies, H1 2014
Products under Development by Companies, H1 2014 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2014
Peritoneal Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2014
Peritoneal Cancer - Pipeline by AstraZeneca PLC, H1 2014
Peritoneal Cancer - Pipeline by GlaxoSmithKline plc, H1 2014
Peritoneal Cancer - Pipeline by Bioniche Life Sciences, Inc., H1 2014
Peritoneal Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2014
Peritoneal Cancer - Pipeline by Oxford BioMedica plc, H1 2014
Peritoneal Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014
Peritoneal Cancer - Pipeline by Novartis AG, H1 2014
Peritoneal Cancer - Pipeline by ImmunoGen, Inc., H1 2014
Peritoneal Cancer - Pipeline by Bayer AG, H1 2014
Peritoneal Cancer - Pipeline by Incyte Corporation, H1 2014
Peritoneal Cancer - Pipeline by Oncolytics Biotech Inc., H1 2014
Peritoneal Cancer - Pipeline by Pharmacyclics, Inc., H1 2014
Peritoneal Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2014
Peritoneal Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2014
Peritoneal Cancer - Pipeline by MabVax Therapeutics, Inc., H1 2014
Peritoneal Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2014
Peritoneal Cancer - Pipeline by Acceleron Pharma, Inc., H1 2014
Peritoneal Cancer - Pipeline by TRION Pharma GmbH, H1 2014
Peritoneal Cancer - Pipeline by CerRx, Inc., H1 2014
Peritoneal Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2014
Peritoneal Cancer - Pipeline by TetraLogic Pharmaceuticals, H1 2014
Peritoneal Cancer - Pipeline by Innate Therapeutics Limited, H1 2014
Peritoneal Cancer - Pipeline by CritiTech, Inc., H1 2014
Peritoneal Cancer - Pipeline by Immunotope, Inc., H1 2014
Peritoneal Cancer - Pipeline by Immunovaccine, Inc., H1 2014
Peritoneal Cancer - Pipeline by Pharma Mar, S.A., H1 2014
Peritoneal Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2014
Peritoneal Cancer - Pipeline by Genelux Corporation, H1 2014
Peritoneal Cancer - Pipeline by Clovis Oncology, Inc., H1 2014
Peritoneal Cancer - Pipeline by California Stem Cell, Inc., H1 2014
Peritoneal Cancer - Pipeline by EGEN, Inc., H1 2014
Peritoneal Cancer - Pipeline by Advanced Accelerator Applications, H1 2014
Assessment by Monotherapy Products, H1 2014
Number of Products by Stage and Target, H1 2014
Number of Products by Stage and Mechanism of Action, H1 2014
Number of Products by Stage and Route of Administration, H1 2014
Number of Products by Stage and Molecule Type, H1 2014
Peritoneal Cancer Therapeutics - Recent Pipeline Updates, H1 2014
Peritoneal Cancer - Dormant Projects, H1 2014
Peritoneal Cancer - Discontinued Products, H1 2014

List of Chart


Number of Products under Development for Peritoneal Cancer, H1 2014
Number of Products under Development for Peritoneal Cancer - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Investigation by Universities/Institutes, H1 2014
Comparative Analysis by Late Stage Development, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Assessment by Monotherapy Products, H1 2014
Number of Products by Top 10 Target, H1 2014
Number of Products by Stage and Top 10 Target, H1 2014
Number of Products by Top 10 Mechanism of Action, H1 2014
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
Number of Products by Top 10 Route of Administration, H1 2014
Number of Products by Stage and Top 10 Route of Administration, H1 2014
Number of Products by Top 10 Molecule Type, H1 2014
Number of Products by Stage and Top 10 Molecule Type, H1 2014

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *